Special Issue

Single-Stage Management of Musculo-Skeletal Infections: Local Antibacterial Protection, Antibiotics, and Surgical Treatments

Message from the Guest Editors

This Special Issue aims to serve as a comprehensive platform for the exchange of cutting-edge research and innovative approaches in the realm of one-stage revision arthroplasty. With the increasing prevalence of prosthetic joint infections, the integration of local antibacterial implant protection techniques, coupled with advancements in antibiotic and surgical treatments, has become paramount in ensuring successful outcomes for patients undergoing revision procedures. We welcome original research articles, reviews, case studies, and perspectives that delve into the latest developments, challenges, and breakthroughs in the field. By contributing to this Special Issue, authors will have the opportunity to shape the discourse around best practices, novel strategies, and emerging technologies in the context of one-stage revision arthroplasty. Your expertise and contributions will undoubtedly enrich the collective knowledge base, fostering advancements that directly impact patient care and outcomes. We look forward to receiving your submissions. Best regards,

Guest Editors

Prof. Dr. Guillem Bori

Department of Orthopaedics, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

Dr. Carlo L. Romanò

Romano Institute ShPK, Tirana, Albania

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/199177

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

